Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial
Martin Bornhaeuser(German Cancer Research Center), Christian Thiede(University Hospital Carl Gustav Carus), Catrin Theuser(University Hospital Carl Gustav Carus), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Alexander Kiani(Bayreuth Medical Center), Cornelia Brendel(Philipps University of Marburg), Thomas Illmer(Center for Systems Biology Dresden), Michael Kiehl(Klinikum Frankfurt Höchst), Hans Martin(Goethe University Frankfurt), Uwe Platzbecker(National Center for Tumor Diseases), Gesine Bug(Goethe University Frankfurt), Stefan Klein(Praxis für Hämatologie und Onkologie), Axel A. Fauser, Johannes Schetelig(University Hospital Carl Gustav Carus), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik), K Lutterbeck(University Hospital Carl Gustav Carus)
Cited by 1
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k